Welcome to our dedicated page for Verastem news (Ticker: VSTM), a resource for investors and traders seeking the latest updates and insights on Verastem stock.
Verastem Oncology (NASDAQ: VSTM) is a clinical-stage biopharmaceutical company pioneering targeted therapies for cancer treatment, with a specialized focus on inhibiting RAF/MEK and FAK signaling pathways. This dedicated news hub provides investors and industry observers with timely updates on the company's progress in developing innovative solutions for treatment-resistant cancers.
Access comprehensive coverage of Verastem's latest developments including clinical trial milestones, regulatory updates, strategic partnerships, and financial results. Our curated news collection serves as an essential resource for tracking advancements in cancer stem cell research and precision oncology programs.
Find authoritative reporting on key initiatives such as VS-6766 (RAF/MEK inhibitor) developments, combination therapy trials, and intellectual property updates. The page consolidates earnings announcements, research publications, and management commentary for efficient due diligence.
Bookmark this page for direct access to verified information about Verastem's pipeline progress and corporate developments. Check regularly for new updates on therapeutic candidates moving through clinical evaluation and their potential implications for cancer care innovation.
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company focused on developing new cancer medicines, has announced the grant of stock options to nine new employees. These options allow the purchase of 109,000 shares of common stock at an exercise price of $2.82 per share, which was the closing price on October 1, 2024.
The grants were made under the Nasdaq inducement grant exception, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options will vest over four years, with 25% vesting on the one-year anniversary of each employee's hire date, and the remaining shares vesting quarterly over the following three years in equal amounts. Vesting is contingent on continued employment or service provision to Verastem Oncology.
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company focused on developing new cancer medicines, has announced its participation in the 2024 Cantor Global Healthcare Conference. The company's management team will engage in a fireside chat on Wednesday, September 18 at 3:40 pm EDT.
Interested parties can access a live webcast of the discussion through the 'Events & Presentations' section of Verastem's website. For those unable to attend live, a replay of the webcast will be available on the company's website for approximately 90 days following the presentation.
Verastem Oncology (VSTM) announced the acceptance of a late-breaking abstract for oral presentation at the International Gynecologic Cancer Society (IGCS) Annual Meeting in October 2024. The presentation will feature mature data from the Phase 2 RAMP 201 clinical trial, evaluating the combination of avutometinib (RAF/MEK clamp) and defactinib (FAK inhibitor) in patients with low-grade serous ovarian cancer (LGSOC).
The presentation will include updated safety and efficacy data, including overall response rate, progression-free survival, and duration of response. Verastem Oncology's CEO, Dan Paterson, highlighted that the robust interim data from RAMP 201 enabled the initiation of a rolling NDA submission to the FDA. The company remains on track to complete its NDA submission in Q4 2024.
Verastem Oncology (NASDAQ: VSTM) and STAAR Ovarian Cancer Foundation have established the first Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024. LGSOC is a rare ovarian cancer often affecting younger women, with no FDA-approved treatments. The initiative aims to educate about LGSOC symptoms, provide resources, and advocate for more research.
Key points:
- Approximately 80% of LGSOC patients experience cancer recurrence
- 99% of surveyed patients had no awareness of LGSOC prior to diagnosis
- 60% felt their healthcare provider was not very knowledgeable about LGSOC
- Verastem is conducting clinical trials for an investigational treatment combination for LGSOC
- The company has initiated a rolling new drug application with the FDA for a potential LGSOC-specific treatment
Verastem Oncology (Nasdaq: VSTM) reported Q2 2024 financial results and business updates. Key highlights include:
1. Initiated rolling NDA submission for avutometinib and defactinib combination in recurrent low-grade serous ovarian cancer.
2. Presented positive initial interim results from RAMP 205 trial in first-line metastatic pancreatic cancer at ASCO 2024.
3. Cash position of $83.4 million as of June 30, 2024; pro forma $144.5 million including recent financing and milestone payment.
4. Q2 2024 revenue of $10 million from COPIKTRA sales milestone.
5. Net loss of $8.3 million, or $0.31 per share for Q2 2024.
6. Expects to complete NDA submission in H2 2024 and potential U.S. commercial launch in 2025.
Verastem Oncology (Nasdaq: VSTM) has received FDA Orphan Drug Designation for avutometinib and defactinib in treating pancreatic cancer. This combination therapy, along with standard chemotherapy, showed promising results in the ongoing RAMP 205 trial for first-line metastatic pancreatic cancer. Initial interim data presented at ASCO 2024 revealed an 83% confirmed partial response rate in the dose level 1 cohort. The company plans to report updated data from the trial in Q1 2025. The Orphan Drug Designation recognizes the unmet need in pancreatic cancer treatment and offers benefits such as tax credits and potential market exclusivity.
Verastem Oncology (Nasdaq: VSTM) has announced the pricing of a $55.0 million public offering of common stock, warrants, and pre-funded warrants. The offering includes 13,333,334 shares of common stock and warrants at $3.00 per share, and 5,000,000 pre-funded warrants with accompanying warrants at $2.999 each. The warrants have an exercise price of $3.50 per share and will expire in 18 months.
The company plans to use the proceeds for the potential launch of avutometinib and defactinib in LGSOC, continued clinical research and development, working capital, and other corporate purposes. Guggenheim Securities and Cantor are acting as joint book-running managers for the offering, which is expected to close on July 25, 2024.
Verastem Oncology (Nasdaq: VSTM) has announced a proposed public offering of common stock, warrants, and pre-funded warrants. The offering, subject to market conditions, aims to raise funds for various purposes including:
1. Potential launch of avutometinib and defactinib in low-grade serous ovarian cancer (LGSOC)
2. Continued clinical research and development
3. Working capital and general corporate purposes
4. Possible acquisitions
Guggenheim Securities and Cantor are acting as joint book-running managers for the offering. The securities will be offered under a shelf registration statement declared effective by the SEC on November 20, 2023.
Verastem Oncology (Nasdaq: VSTM) announced that the first patient has been dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) inhibitor, in a Phase 1/2 trial in China. Conducted by GenFleet Therapeutics, this trial is part of a collaboration established in 2023. The trial aims to evaluate GFH375/VS-7375's safety and efficacy in patients with advanced KRAS G12D mutant solid tumors. Initial preclinical data showed strong anti-tumor activity and potential for brain metastases treatment. Verastem plans to initiate development studies outside China after analyzing the Phase 1 dose escalation data.
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical firm, has announced inducement grants under Nasdaq Rule 5635(c)(4). The company granted stock options for 108,292 shares to seven new employees to incentivize their employment.
The stock options, priced at $3.25 per share, reflect the closing price on July 1, 2024. Options for 78,292 shares will vest 25% after one year, with the remaining shares vesting quarterly over three years. Meanwhile, options for 30,000 shares will vest upon meeting specific regulatory milestones, contingent on continued employment.
